Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What industry news are you referring to?
Are you referring to this Diagnostic and Interventional Cardiology article discussing the increasing interest in developing cardiac PET centers:
https://www.dicardiology.com/article/how-start-cardiac-pet-ct-imaging-program
I also see this news that PSU/St. Joseph's bought a cardiac PET scanner that makes no mention of CT, so I have to wonder of that's actually one of Positron's machines, since I think they are still the only manufacturer offering PET-only scanners w/o CT:
https://news.psu.edu/story/606710/2020/02/04/impact/penn-state-health-st-joseph-spring-ridge-offers-expanded-services
My searches aren't turning up any other recent news of significance, so please provide some more specifics!
P.S.: I picked up the 21,797 shares on 1/29 @ $0.16 to round out my position in my brokerage account.
SIM.v/SYATF: I'll be watching this website to see if the Uniden UV350 shows up in their offerings.
https://www.motorolasolutions.com/en_us/products/lte-user-devices.html
I've been following the company since I met them at the MicrocapClub Leadership Summit in 2017, always been very compelling, but hasn't gained traction much sales traction yet......this might be the relationship that finally gives them traction that could lead to a nice long-term growth story.....I'll be watching for verification before going in though.
SMSI just bought their competitor that serves T-Mobile, aleviating any concern that the merged company might go with the competition:
https://finance.yahoo.com/news/smith-micro-acquires-operator-business-130000168.html
LCI: Evidwnce is mounting, showing Kaletra has some possitive effect.
On LCI's earnings call they said they were in discussions with a partner about importing Kaletra. (24:00).
Thanks for verifying that the company is still working on updating their filings. I don't think recent trading reflects anything fundamentally negative, other than the fact the float is largely owned by impatient penny flippers, recent volume has been pretty minimal relative to the 61 million unrestricted shares. The stock has traded 86,948,846 since June 11, 2019, but has only traded 14,270,630 since hitting the high of $0.033 on December 13th.
I did most of the buying today on the bid, I picked up another 708,900 shares today. Based on my review of their past filings, their audited account statements they posted to their website to prove their 168% return over 36 months, and Potse's find on their archived website stating they had reached break even....I think there's a good possibility these current prices might be near their current cash value.
"The stock market is a device for transferring money from the impatient to the patient." - Warren Buffett.
LCI: During their earnings call an analyst asked about the impact of Coronavirus, the CEO said they had the only ANDA for Kaletra and they had been contacted by a partner about importing it into China, but then tempered that statement by saying that its not a big market for them and there's other sources of it on the global market as well. This started around the 24:00 mark in the call available on their website.
I think there's a 50/50 chance that partner follows through with importing it and that becomes public information.....and if that happens, there's a good chance the stock catches the Coronavirus momo and runs 20% or more.
LCI running hard into earnings after the bell today. I've e-mailed the analysts who participated in previous earnings CCs with a couple of news articles about Kaletra and Coronavirus, hoping to hear one of them ask something on the call this afternoon. My calls options have doubled so far....thinking I should take half of the table before the close to cover my cost and let the rest ride on the earnings news and cc. Thanks again for a good idea yielddude!
R-Pharm hiking production of Kaletra for treatment of Chinese coronavirus
https://www.thepharmaletter.com/article/r-pharm-hiking-production-of-kaletra-for-treatment-of-chinese-coronavirus
Good news, seems like only a matter of time before the market discovers LCI makes a generic Kaletra...and is in a much better position to actually benefit from this than most other coronovirus plays.
https://www.smartbrief.com/s/2017/01/lannetts-generic-hiv-treatment-wins-fda-nod
One of few bright spots in the 4th quarter was development and consulting revenues. The MD&A indicates:
Development and consulting services revenue for the three month period ended September 30, 2019 increased by 58% to $1,201,981, compared to $760,326 for the same period of the prior year. Revenue from development and consulting services varies based on opportunities and the length of the sales cycle for given projects.
That seems to correspond to this increase in OEM clients mentioned in the PR: We engaged in over 60 customer development projects of various sizes with approximately 22 medical product companies this past year in our OEM business, which includes the various projects underway associated with the previously announced major contract with one of the world’s largest
medical device companies that licensed Covalon’s proprietary medical coating technologies.
Covalon Technologies Ltd (UK) is building a portfolio of case studies for Covalon's Advanced Wound Care Products:
https://www.covalon.co.uk/Resources.html#performance
Conference Call Scheduled
A conference call to discuss Covalon’s Fiscal 2019 Year-End Financial Results will be held Wednesday, January 29th, 2020 at 9:00am EST. To participate in the call, please dial:
Toll-Free: 833.299.8117
Canada: 647.689.4535
Conference ID Code: 5092807
A recording of the call will be available by calling 855.859.2056 or 404.537.3406 and entering the
conference ID code 5092807 from January 29th, 2020, at 12:00pm EST to February 12th, 2020, at 11:59pm EST.
Covalon Announces Fiscal 2019 Year-End Results and Plans for Fiscal 2020
• Fiscal 2019 revenue growth of 27% to $34 million of revenue.
• Fiscal 2019 United States revenue of $24 million, double the Company’s fiscal 2018 United States revenue.
• Fiscal 2019 Middle East revenue of $8.8 million impacted by delayed shipments and regional uncertainty.
• Latin America and Europe to provide some additional revenue upside in fiscal 2020 and beyond.
MISSISSAUGA, Ontario – January 28, 2020 – /Business Wire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announces
its fiscal 2019 year-end results and plans for fiscal 2020.
Brian Pedlar, Covalon’s President and CEO, said, “Fiscal 2019 saw Covalon undergo significant changes as an organization, which have strengthened our business model and provided us with a very strong platform for future growth. Our major achievements during fiscal 2019 included:
• Completing the acquisition of U.S.-based AquaGuard, which provides Covalon with almost 2,000 new hospital and medical institutions as customers in the United States and a talented and experienced sales force selling infection prevention products directly into hospitals;
• Strong growth in our development and consulting services revenue following the signing of the previously announced major contract with one of the world’s largest medical device companies that licensed Covalon’s proprietary medical coating technologies; and
• Completion of product registration for Covalon’s flagship products in most Latin American countries, including Mexico, Argentina and Chile, enabling Covalon to compete for business in these markets in fiscal 2020 and beyond.”
Mr. Pedlar continued, “Over the past two years, Covalon has become a significantly stronger and more diverse company:
• We added 35 people to our sales and marketing teams, which means more people selling our products;
• We now have nearly 2,000 new hospital, clinic, group purchasing organizations, and integrated delivery network customers in the United States that provide a new customer base for our existing products;
• We have begun to distribute our products in 16 new countries that will begin to materially contribute to revenue;
• We now have four product families that each account for 20% or more of our annual revenue, which provides stability and diversification for our business;
• We have four new products that we have yet to launch in our key markets;
• We have exciting new products in our pipeline that we intend to launch this year, including a significantly improved version of our flagship IV Clear product; and
• We engaged in over 60 customer development projects of various sizes with approximately 22 medical product companies this past year in our OEM business, which includes the various projects underway associated with the previously announced major contract with one of the world’s largest medical device companies that licensed Covalon’s proprietary medical coating technologies.
“We are just at the beginning of our growth as a result of these key changes to Covalon and are at the early stages of introducing our expanded product portfolio to our new hospital customers in the United States.
Our Middle East business declined in fiscal 2019 compared to 2018 as a result of significant delays in shipments under the contracts we secured in Saudi Arabia. Though it is still very difficult to predict the
volume and timing of business in Saudi Arabia, particularly in light of the current regional uncertainty, our business in the region has continued, and we are working to grow it further. We have made changes to our operations during the second half of fiscal 2019 and first quarter 2020 that I believe will see Covalon reduce its operating expenses by up to $7 million in fiscal 2020 compared to fiscal 2019. We are also well-positioned for growth in the United States, Latin America, and Europe, and we are optimistic about our potential for significant growth in fiscal 2020 and 2021.
“I am extremely confident in Covalon’s present commercialization position and its upside potential. Our unique suite of life-saving products and our dedicated and driven staff have always set us apart from the competition, and we continue to leverage those strengths as we grow our business. Our share price declined this past year due to uncertainty in our Middle East business. Many shareholders, who saw the
challenges we experienced in the Middle East as temporary headwinds, took the opportunity to invest more in Covalon either in the public markets or by participating in the private placement we closed in
September 2019. I am confident that they will be rewarded when Covalon’s underlying value gets reflected in its share price.”
Fiscal 2019 Financial Results
Revenue for the year ended September 30, 2019 was $34 million, 27% or $7,281,280 more than the prior year. Gross profit was $21.8 million in fiscal 2019, compared to $19.7 million in fiscal 2018. Net loss was
$9.1 million or $0.41 per share (diluted), compared to a net income of $1.6 million or $0.07 per share (diluted) in fiscal 2018.
Product revenue for fiscal 2019 increased to $30 million, compared to $19.9 million in the previous year.
This increase relates to the inclusion of revenue from the acquisition of AquaGuard and the timing of major shipments.
Gross margin was 64% for fiscal 2019, compared to 74% for the prior year. Gross margin is highly influenced by the mix of collagen-based dressings, silicone-based dressings, medical coated devices, passive dressings, moisture barriers, and related service revenues generated in the periods. Gross margin fluctuates as a result of the mix of products sold in any given quarter, or year, by product type or geography.
Operating expenses increased $12 million to $30 million, compared to $18 million for the prior year. The increase in operating expenses is primarily related to increases in sales and marketing costs and general
and administrative expenses as a result of acquiring AquaGuard on October 1, 2018. The Company also increased headcount in operations, sales and marketing, and administration as a result of the Company’s
efforts to expand its penetration of new markets, including Europe and the United States.
Fiscal 2019 saw the Company end the year with a strengthened and more diversified revenue base. In fiscal 2019, approximately 71% of revenue was from sales in the United States and 26% of revenue was
from sales in the Middle East. Last year was 48% in the United States and 49% in the Middle East.
Conference Call Scheduled
A conference call to discuss Covalon’s Fiscal 2019 Year-End Financial Results will be held Wednesday, January 29th, 2020 at 9:00am EST. To participate in the call, please dial:
Toll-Free: 833.299.8117
Canada: 647.689.4535
Conference ID Code: 5092807
A recording of the call will be available by calling 855.859.2056 or 404.537.3406 and entering the
conference ID code 5092807 from January 29th, 2020, at 12:00pm EST to February 12th, 2020, at 11:59pm EST.
To learn more about Covalon, please contact:
Brian Pedlar, CEO, Covalon Technologies Ltd.
Email: bpedlar@covalon.com
Phone: 905.568.8400 x 233
Toll free: 1.877.711.6055
Web site: www.covalon.com
Twitter: @covalon
About Covalon
Covalon Technologies Ltd. researches, develops, and commercializes new healthcare technologies that help save lives around the world. Covalon's patented technologies, products, and services address the
advanced healthcare needs of medical device companies, healthcare providers, and individual consumers. Covalon's technologies are used to prevent, detect, and manage medical conditions in specialty areas such as infection control, vascular access, surgical procedures, advanced wound care, and medical device coatings. To learn more about Covalon, visit our website at www.covalon.com
Nice find yielddude, I decided to play LCI with some Feb 21 '20 $10 calls.
In addition the potential for their generic Kaletra, a couple other potential catalysts include their earnings report next week and the fact JPMorgan just filed a 13G last Friday showing they increased their ownership to 2,765,513 from the 2,352,628 Yahoo! indicates they reported on 9/29/19.
P.S. - Glad to see you back active on the boards, I hope you're timing proves to be opportune!
LOL! I'm glad someone is listening! eom
Nice entry! I'm not sure the tariffs are coming off of Zoom's products, but I am sure Zoom is shifting manufacturing this quarter to get out from underneath the tariffs on their own terms.
What's more, Zoom is customizing Motorola's next generation modems and routers with features the ISPs and MSO's want to make them their preferred choice for Customer Premises Equipment (CPE), which will also enable Zoom to provide high demand services for WiFi management, IoT security, and parental controls on screen time and content.....as well as other services the market hasn't even envisioned yet.
I like the changes the company has made over the past year by adding visionary leadership to the BOD, connected broadband salespeople to management, and I have locked down my position to see how this develops in the long term.
There's a lot of tough history here for this company and its shareholders, but the fact the company survived and positioned itself to benefit from the mainstream adoption of cardiac PET over the next couple of years could finally make it all worthwhile for the long suffering shareholders.
I accumulated the bulk of my position during the weakness the stock saw during 2018 tax loss selling under $0.05 and didn't put a single share up for sale during this recent spike to $1 because I believe these could be worth multiples more than $1 in a few years, once Flurpiridaz is approved and gives cardiac PET a clear advantage over SPECT (with it's clinical trial's last patient follow-up expected in August 2020) and good execution by Positron in making the most cost effective scanners for small and medium cardiac practices.
I'll continue to accumulate on any weakness, but hope to see the company begin to catch up with filings and relisting soon, so that we can watch their growth story begin to unfold over the next few years in public filings.
ZMTP: Wirecutter Selects Motorola MB7621 Cable Modem as The Best Modem For Most People
1:47 PM ET 12/30/19 | GlobeNewswire
Wirecutter Selects Motorola MB7621 Cable Modem as "The Best Modem For Most People"
Recommends Motorola MB8600 DOCSIS 3.1 Cable Modem for Gigabit Internet Plans
Boston, MA, Dec. 30, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE --Zoom Telephonics, Inc. ("Zoom" or "the Company") (OTCQB: ZMTP), a leading producer of cable modems and other communication products, today announced its very favorable ratings in Wirecutter's "The Best Cable Modem" article updated December 19, 2019. Wirecutter, a New York Times company, recommends "the best gear and gadgets for people who want to save the time and stress of figuring out what to buy." Their recommendations "are made through vigorous reporting, interviewing, and testing by teams of veteran journalists, scientists, and researchers." "The Best Cable Modem" article recommends the Motorola MB7621 DOCSIS 3.0 cable modem as "the best modem for most people." For people using Gigabit cable Internet plans, Wirecutter recommends the Motorola MB8600 DOCSIS 3.1 cable modem.
The complete article is currently at: https://thewirecutter.com/reviews/best-cable-modem/
Wirecutter's review notes that its staff researched nearly 100 modems over the past five years and determined as of December 19, 2019 that the MB7621 is the best modem for most people looking to save money by buying their own cable modem rather than renting one from an Internet Service Provider each month. Cable modem rental fees depend on the cable Internet provider and can be as high as $13 per month. Model MB7621 normally retails for $77.99, and Model MB8600 normally retails for $159.99, with both available at leading retailers nationwide.
Management Commentary
Frank Manning, Zoom's CEO, commented: "Wirecutter is highly respected, and we're honored by this article's selections. We've worked hard to design a superb line of cable modems and cable modem/routers, and we appreciate the recognition our products have achieved from Wirecutter."
Joe Wytanis, Zoom's President, commented: "Buying your own cable modem is a smart choice for many Americans, and we agree that our Motorola MB7621 and MB8600 are best in class. For those cable Internet customers who want a high-speed cable modem that also has a built-in high-performance router and telephone capability, we recommend the Motorola MT7711."
About Zoom Telephonics
Zoom Telephonics, Inc. designs, produces, markets, and supports cable modems and other communication products. The Company's worldwide Motorola license agreement includes cable modems and gateways, local area network products including routers and MoCA Adapters, DSL modems and gateways, cellular modems and routers and sensors, and other Internet and network products. For more information about Zoom and its products, please visit www.zoom.net and www.motorolanetwork.com.
MOTOROLA and the Stylized M Logo are trademarks or registered trademarks of Motorola Trademark Holdings, LLC and are used under license.
Investor Relations Contact:
Jeremy Hellman, Vice-President
The Equity Group Inc.
Phone: 212-836-9626
Email: jhellman@equityny.com
> Dow Jones Newswires
I presented ZMTP as my favorite investment idea for the year ahead at The Microcap Leadership Summit in September 2019.
My case for share price appreciation in the year ahead was based on these three points:
1.) At the time, the company's share price was being too highly discounted at $0.75 due to largely temporary problems of tariffs that they are dilligently working to remedy. Further to that point, I believe last quarters earnings report demonstrated good growth and progress on margins as the company has plans to shift most of its manufacturing out of China in the coming quarter. If you subtract the ~$1 million the company paid in tariffs, they would have reported ~$800k in profits, or $0.04 EPS.
2.) The company's recent sales and marketing staff additions and their strong contacts and histories of selling into large ISPs and MSOs could drive substantial growth if they see success in this strategy. Motorola used to be a preferred brand of many network operators for customer premesis equipment (CPE) and this should be a fairly easy sell once products are updated with this goal in mind. Joe Wytanis made some comments on last quarters call that new product introductions expected in early 2020 have been designed with input from these prospective customers, so I remain optimistic about this strategy bearing fruit.
3.) The recent investment from Jeremy Hitchcock and alliance with his company, Minim, gives ZMTP a low risk, low investment foot in the door to selling home network security services (IoT, WiFi, and parental controls) and could strengthen ZMTP's prospects for selling CPE into the ISPs and MSOs who are looking to white-label Minims software and offer it to their customers, as well as strengthens ZMTP's direct to consumer offerings with ZMTP's own white-labeled version of Minim's software tools for managed Wifi, IoT security and parental controls.
I think 2020 has good potential to be a transformative year for this company as it focusses on these strategies for profitable growth.
I made ZMTP is a core holding of mine in the $0.80 cent range over the summer of 2019 and am looking to hold it for long term gains on a rebound to its former highs over $3 or more per share based only on success in point 1 above, they have blue sky potential for the upside with their sales strategy targeting service operators and home network security applications.
I would say some inexperienced investors/traders (perhaps doctors) are making the stock go crazy because they are excited about what is going on in the industry and they want in because they the know the company is well positioned to capitalize on the emerging industry trends.
This article does a nice job of summarizing why the industry trends are going to be creating a favorable playing field for PET scanning in general, and Positron Corp. in particular:
https://www.dicardiology.com/article/6-trends-cardiac-nuclear-imaging-asnc-2019-meeting
"Forget FFR-CT, do PET studies and you may get a better result," Mahmarian said. "I think the future of nuclear imaging is bright."
.....
Beanlands said there also is increasing interest in PET imaging because of its superior image quality, speed of the exam and increasing access to PET radiotracers. New tracers on the horizon also will increase the image quality and flexibility of PET to accommodate exercise stress. He said single photon emission computed tomography (SPECT) has been the standard for cardiac nuclear imaging for decades, but PET offers improved image quality for more precise diagnosis.
.....
Flurpiridaz F-18 PET perfusion agent that offers high quality images and can be used with exercise stress;
Even with the ask at a $1, I didn't put in any sell orders, I do think this has potential to be worth more in a few years as these industry trends play out.
Nice move today, I expect this may move may eventually be supported with more significant volume, once the company is ready to share their updated financials and outlook.
SMSI: Prices dropped to $3.70 now. I just made my play on this situation with the April 2020 $4 call Options @ $0.50 per contract, so I need the stock to trade back over $4.50 sometime before April 17th.
First, I think the stock is currently under pressure from warrant conversions and tax loss selling and could bounce early in the new year, the chart sure looks ready for a bounce soon.
Secondly, closing arguments of the Sprint - T-Mobile merger are scheduled for January 15, 2020. SMSI has traded up on good news from that hearing, so there's a possible good play in the outcome there.
Finally, there's a tendency for high growth NASDAQ stocks to run up before earnings while markets are hot, and I expect there's a good chance we could see one of those runs on SMSI in early March.
It's a small "gambling money" position for me, but I like SMSI's SafePath platform growth and profitability and might actually consider exercising the warrants @ $4 in March if the Sprint/T-Mobil merger were to be rejected and SMSI would have a relatively more stable outlook for continued growth of that offering under Sprint.
SPRT: Thanks hweb, but for further clarification, do you know if the shares need to have "cleared" by the ex-div date? If that's the case, then one would need to buy on the 23rd for them to have cleared on the third trading day afterwards on the 26th.
I only became familiar with this 25% rule about a year ago on HYDI when I bought during the sell off after the "record date" and was pleasantly surprised to get the divy as well about 10 days later!
I wouldn't want to but this on the 24th for $1.90 to find out I wasn't getting the dividend....but want a little more time to evaluate the business this weekend before I decide what I want to do.....the CEO purchase is a strong indicator there's more than a cigar butt here....and the embers may ignite a new growth story.
SMSI....looking to initiate a position, but thought that waiting out the tax loss selling and warrant liquidations might give me a better opportunity....that might be happening now.
Also, seems the market runs-up SMSI stock price on good news for the Sprint / T-Mobile merger and punishes it for bad news. As I see it, I'd rather have the certainty of Sprint as a stand alone and would gladly buy during any sell-off on confirmation they will back out of their merger plans.
Sitting on the edge of my seat to initiate a position in what should be a good long-term growth and earnings story.....unless the merger goes through and T-Mobile's aps are the move forward plan.
A little actual buying at the ask the past few days....it's been quite a while since we've seen a motivated buyer sniffing around here!
Hopefully a sign the companing is getting closer to coming out of the dark, or maybe just a new customer who likes the fundamentals behind their own investment in a cardiac PET scanner for their practice and sees the opportunity in our equity as well.
I can wait, I do think 2020 is going to be a breakout year for demand for cardiac PET!
The company deregistered with the SEC in 2016, there won't be any 8ks.
The company needs to get their financials caught up for compliance with the OTC alternative reporting standards so we can at least get an idea of what it is we hold here.
Kind of hard to put a valuation on it when we only have three year old numbers to look at; but with the $2.7 million in cash they had at August 31, 2015 and the audited account statements showing the returns on their trading platform through December 29, 2017, and the statement Potse found from the archived website saying they achieved break-even operations.....there's a chance this might be trading near the amount of cash they have on the books still.
I should hope they get their financials updated soon to give investors a fair look at what we own here.
Seems like Mitsubishi got quite a deal considering the AccessScientific's planned expansion of distribution to Smith's Medical that e-ore had pointed out a few months ago:
https://accessscientific.com/announcements/
This was one of my most intrguing prospects, I though the sales and the stock had quite a runway ahead of them with the Access Scientific / Smith's agreement in the works.....I hope management at least secured themselves some golden compensation plans with Mitsubishi. If I was a shareholder, I'd vote against it.
Anyone buying this should also be made aware of the Bankruptcy filing indicating that Class 6 Creditors (Insiders) hold a $1,266,849 convertible note that could be converted at a 45% discount to the market. It's discussed in Section 4.8 of the Exhibits filed with the SEC here:
https://www.bamsec.com/filing/161577418007286/3?cik=844985
That could be some significant dilution from our current low O/S. With the current share price @ $0.14, the 45% discount would price shares @ $0.077, which would amount to 16,542,545 shares being issued (not accounting for any interest on the note).
I've been told the note holders are "friendly" to current shareholders, appreciate the value of tight capital structure, and are not going to look to play manipulative games with the stock price prior to conversion.
All that being said, I still really like this company's potential once Lantheus's Flurpiridaz F-18 imaging agent gets approval, which is expected in about a year, and will probably give PET a distinctive advantage over SPECT for imaging accuracy/price/ and half life (allowing exercise induced stress):
http://www.lantheus.com/pipeline/flurpiridaz-f-18/
Why? There's man reasons. The company is dark, there's an extremely thin market for their shares, such that the spread is at 0.062/0.15, which is more than a 100% difference.
I picked up some shares last year around this time as they were being thrown out for tax losses @$0.05 and under.
I think cardiac PET is better than SPECT and the company announced last year they had made some sales, which caught my attention. I called the company and asked if they were tow seperate sales, as they curiously released the same generic PR on different dates (9/6/2018 to their website and 10/2/2018 to the newswire), their President told me that had made multiple sales in the past year after not making any since 2013, that there was a watershed moment in cardiac PET happening with newer studies and the scarcity of Tc-99 for SPECT at the time.
Great news, thanks for the update!
Looks like SNMMI worked diligently with ACC, ASNC, and CAA to keep Cardiac PET MPI reimbursable by CMS at economically reasonable levels:
http://www.snmmi.org/NewsPublications/NewsDetail.aspx?ItemNumber=32960
To be honest, I didn't even know this issue was brewing, but hopefully this assurance or economical reimbursement rates helps Positron get some more sales through their funnel and enables them to come out of the dark with a stronger business case for investors than they've had in the past decade or longer.
Some insider buying.
https://www.otcmarkets.com/filing/html?id=13702079&guid=4MYSUHUxZWEwi3h
Market regulators (FIRNA or IIROC in Canada) sometimes contact companies experiencing unusual trading activity and request them to either halt trading until they issue a news release, or to issue a statement that no material change has taken place, I think that's the reason for the statement of published on www.epcylon.com. (FWIW here's an example of that in Canada: https://www.businesswire.com/news/home/20180418006040/en/Covalon-Unaware-Material-Change)
While the Bridge Rock Tech website just went up recently, I don't think it contains anything really new or exciting to explain the recent spike of interest in the stock.
I think what may have caused the spike of interest is someone may have just just noticed the information contained at the bottom of Potse's !!!POST# 314!!! Go back and re-read that, click all the links, then go verify who James. K Lau is!!! Mean Wiemaraner made some interesting follow ups as well.
For some reason (unknown to any of us yet) on May 8th the company increased their authorized shares and designated 15M preferred shares. Then on May 29, 2019, Epcylon registered domain names: jamesonam.com and jameson-asset.com, which identifies James K. Lau as a Principal. Those websites are active and also show the same physical address as Bridgerock Technologies in Toronto.
That's why I'm interested here, James Lau has a very impressive resume in building a Canadian chartered bank from the ground up. He doesn't have much of a public profile, but his accomplishments of founding and growing a Forex company into a chartered bank in Canada is impressive.
https://www.investmentexecutive.com/news/industry-news/jameson-becomes-canadas-newest-schedule-i-bank/
https://www.pehub.com/canada/2014/04/afex-to-acquire-pe-backed-payment-and-fx-specialist-jameson-bank/
OT: Maybe you should go create your own board and everyone interested in your posts can follow you there?
FCCG: No, I sold it near break even a while ago, it felt like it was going to be dead money for a while, so I needed to find somewhere I could lose my money faster, lol!
Andy said he wanted to merge FCCG into FAT sometime in 2018 or 2019, this interview still seems relevant regarding that strategy:
http://regaresearch.com/2018/05/03/investors-might-have-overlooked-this-juicy-merger-on-fats-menu/
I understand there's lots of shareholders out there that got burned, I've followed this company for 15 years or so myself, but never really saw much value until last year when the stock was in the pennies after the reverse split, during tax-loss selling season, and as the company reported their first system sales in years.
A closer look revealed that PET MPI was being proven superior to SPECT in several clinical studies and the previous scarcity of Rb-82 radiopharmacueticals had been addressed with the entry of a new Rb-82 generator to the market:
https://www.jstage.jst.go.jp/article/anc/3/1/3_17-00047/_pdf
A second Phase III trial for Flurpiridaz-18 sponsored by GE seems to show even greater promise for improved contrast, longer half life allowing for exercise stress testing, rather than drug-induced stress testing. This older article documents the advantages of F-18:
https://www.itnonline.com/article/flurpiridaz-f-18-may-expand-pet-myocardial-perfusion-imaging
This January 2019 SNMMI newsletter shows the traction they are gaining:
"Studies have shown that PET-MPI provides higher diagnostic accuracy than SPECT-MPI for detection of coronary artery disease,
having a higher sensitivity and specificity as well as lower
radiation dose during a shorter examination time period3.
Despite this, some insurance companies will not cover the cost
of the MPI study without an equivocal positive or negative
finding from other diagnostic methods.
http://snmmi.files.cms-plus.com/docs/CTN/Jan_2019Pathways.pdf
I appreciate that the company is more focused on building their business than issuing PR at this point, this is the type of situation I like to invest in, as a patient, long-term investor.
Should be seeing an update on the N8 Medical CeraShield® Endotracheal Tube before year end, the study has an estimated completion date of October 30, 2019.
This has been slow to develop and has flown under the radar, but could bring some excitement before year end.
For background, in June of 2012 Hydromer announced a Strategic Development Agreement with N8 Medical (1) to co-develop a new antimicrobial coating technology using Hydromer’s coating technology in combination with N8’s Ceragenins, a new class of antimicrobial agents developed at Brigham Young University designed to mimic the broad spectrum activity of the human innate immune system. The terms of the agreement were not specified in the PR or subsequent SEC filings, however, the discussion of the relationship appears to be more than Hydromer’s typical “Stand-still Agreements” and “Supply and Support Agreements” they have engaged in with more than three dozen partners with in the past.
Then in May 2017 N8 Medical announced the FDA granted N8 Medical’s CeraShield Endotracheal Tube (ETT) a “Breakthrough Device” designation, due to the significant threat of infection intubation causes for more than four million healthcare patients in the U.S. each year (2) N8 Medical supported its filing with the FDA with recent data from the U.S. Centers for Disease Control and Prevention (CDC) demonstrating that the antimicrobial compound contained in the CeraShield™ Endotracheal Tube inhibited growth of all 100 strains of Candida auris—an emerging, highly-lethal fungal infection. Further, the May 2017 PR stated: “The CeraShield™ medical device coating technology is applicable to a broad range of medical devices commonly colonized with pathogenic bacteria and fungi, including devices for urology, vascular access, cardiology, orthopedics, and ear nose and throat (ENT), as well as other respiratory devices such as tracheostomy tubes. N8 Medical is working to pursue broad application of its CeraShield™ coating technology to create best-in-class antimicrobial medical devices designed to reduce the morbidity and, mortality and high costs and use of resources associated with hospital-acquired infections worldwide—both through independent commercialization efforts and through collaboration and partnering opportunities.”
N8 does not mention the association with Hydromer in their May 2017 PR, but does identify Hydromer as the supplier of the “optimized CeraShield hydrogel coating containing CSA-131” in a very compelling November 2017 PR (3) that goes on to state: “The optimized CeraShield™ hydrogel coatings containing CSA-131 provided controlled slow release of CSA-131, with concentrations released of less than 1ug/ml per 24 hours. The eluting CSA-131 prevented fungal and bacterial colonization of coated ETTs exposed to high inocula for up to 14 days, while uncoated ETTs had extensive biofilm growth after 24 hours. CeraShield™ coated ETTs were well tolerated in intubated pigs. The authors also found that the CeraShield™ ETTs also significantly reduced endotoxin levels.”
N8’s November 2017 PR mentions their intention to initiate clinical trials in the first quarter of 2018; however ClinicalTrials.gov indicates the Feasibility Study was scheduled to begin in October 2018 and conclude January 30, 2019, which has been delayed to October 30, 2019 (4).
(1) https://www.biospace.com/article/releases/hydromer-inc-enters-into-a-strategic-development-agreement-with-n8-medical-inc-for-a-new-class-of-antimicrobial-coatings-/
(2) http://n8medical.com/2017/05/17/antidepressant-medication-come-with-dangers-studies-show/
(3) https://www.n8medical.com/2017/11/03/n8-medical-announces-compelling-publication-supporting-its-breakthrough-cerashield-endotracheal-tube/
(4) https://clinicaltrials.gov/ct2/show/NCT03716713
FCCG: If I had to guess, I would think that some of the investment bankers setting up the FAT preferred stock offerings must have taken notice of the ownership structure and valuation disparity we've been talking about for the past couple of years now.
If I understand this offering correctly, it appears that this secondary offering is going to take debt of FCCG's books and increase the book value of their FAT shares.
I accumulated a little more than 235,000 shares here over the past year between $0.035 and $0.12.
First I must disclose the risk, there is a large dilution risk of the outstanding unsecured notes being converted. In the bankruptcy docs filed with the SEC, this conversion is specified under Class 6 Creditors, Section 4.8. Page 5 of 11, of Exhibit 1, to this link explains the terms of their unsecured notes: https://www.bamsec.com/filing/161577418007286/3?cik=844985
As you can see, there was about $1.1 million of unsecured debt outstanding, subject to conversion at a 45% discount to the current price of the stock. So at the current $0.10/share, that would be $0.055 conversion price for 20,000,000 more shares, giving us a company majority controlled by the creditor. I've been in contact with Adel Abdullah, he said: the creditor(s) have represented that they will be very fair in conversion as they all know many of our shareholder base. I’m confident they will be converting in near future and at a fair value which I suspect is at current levels.
In spite of these financial challenges, the company is making sales thanks to the support of new research that proves PET MPI imaging is superior to SPECT in quality of imaging, thus catching a higher percentage of the at risk population and reducing the amount of radiation exposure. Here's the summary of one such recent study: https://www.sciencedaily.com/releases/2018/03/180310165832.htm
Dr. Lance Gould at the University of Texas, Health Science Center at Houston is one of the key researchers advancing R&D that proves PET is superior to SPECT, he also provides data that helps refine Positron's coronary Flow Reserve (CFR) data overlay, in addition to other researchers and practicioners:
https://www.eurekalert.org/pub_releases/2018-02/uoth-ukl022718.php
Positron's advantage in the market is that they are the only company making a dedicated cardiac PET camera without a CT tube, because CT tubes are an expensive component with a relatively short lifespan that significantly increase cost of ownership for the dedicated cardiology practice, which has little use for the CT in their practice.
During my conversation, I also asked Adel about the two identical PRs about sales, one released on the company's website on 9/6/2018 and one released to the newswire on 10/2/2018. Adel explained that this was not a one-off sale, but that the company had begun making multiple sales again in 2018 after not making any sales for about a five year period from 2013 when they declared bankruptcy.
I wouldn't say opening a US subsidiary would be for "no reason". As a matter of fact, it seems more reasonable to me than the prevailing assumption on this board that Saean is just going to dilute their current investors and those presently making investments, by 29%, by folding Saean Inc. as a whole, into this shell at a 1:1 ratio without a reverse split.
I've read the 8ks. I find it interesting that they explicitly state the conditions of conversion exempt reverse and forward splits, or any other capital reorganization:
(b) Conversion Price
The Exercise Price is $0.03 per share of Common Stock of the Company (e.g. see “Notice of Conversion” attached hereto as Exhibit “D”). The Exercise Price shall not be affected by a reverse or forward split of the Common Stock of the Company, or any other corporate capital reorganization that may have a similar effect as set forth under section 3.3 below.
(c) Adjustments for Stok Splits and Combinations
If the Company shall at any time or from time to time effectuate a reverse or forward split or subdivision of the issued and outstanding Common Stock, the Exercise Price as set forth under subsection 2(b) above shall not be proportionately increased or decreased accordingly. In short, the Exercise Price shall not be affected by a reverse or forward split of the Common Stock of the Company or any other corporate capital reorganization that may have a similar effect.
Potse, could you update us on your views and positioning here? What's your read on the recent 8ks and PRs? Do you still think this is a shell Saean Motors would intend to reverse merge into, or do you think the news reference of a "collaboration" points to more of a US subsidiary kind of relationship?